Agree with a lot of what you are suggesting, although I can't imagine Mr Dewhurst significantly diluting his position at these prices? Also feel the public may not get an opportunity with any CR as they seemed focus on 'strategic' relationships…..
They have previously stated that the new CFO & COO roles are to be separate with the focus on the US already seeing some roles based there. Increased staff costs would reflect these new positions.
The repositioning comment I agree is an interesting one, maybe they are just going to take it private……repackage it and list in the USA, or maybe they have buyout interest? now that the tech is gaining traction and market awareness is rising Globally.
I've regathered up to my free carry amount lately, so happy to sit and watch this unfold.
There is no doubt in my mind that Mr Dewhurst wouldn't put his or his entities money into a dog.
- Forums
- ASX - By Stock
- RNO
- Ann: Business Update & Appendix 4C
Ann: Business Update & Appendix 4C, page-6
Featured News
Add RNO (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online